SWOG clinical trial number
SWOG-8894 (INT-0105) (EST-2889)

A Comparison of Bilateral Orchiectomy with or without Flutamide for the Treatment of Patients with Histologically Confirmed Stage D2 Prostate Cancer

Closed
Phase
III
Accrual
100%
Published
Abbreviated Title
A Comparison of Bilateral Orchiectomy with or without Flutamide for the Treatment of Patients with Histologically Confirmed Stage D2 Prostate Cancer
Activated
12/15/1989
Closed
09/15/1994

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

2018

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

The association between ASCO Value framework and scientific and clinical impact of SWOG phase III clinical trials

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

2014

Enhancing nurse contributions to SWOG clinical trials

L Hansen;C Moinpour;R Ermete Seminars in Nursing Oncology 30(1):26-31;

PMid: PMID24559777 | PMC number: PMC3961058

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

2012

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 & S9346)

C Tangen;M Hussain;C Higano;M Eisenberger;E Small;G Wilding;B Donnelly;PM Venner;P Schellhammer;ED Crawford;N Vogelzang;I Powell;IM Thompson Journal of Urology 188(4):1164-1169;

PMid: PMID22921015 | PMC number: PMC3481164

2010

Improved overall survival (OS) of patients (pts) with new metastatic prostate cancer (PCa): better efficacy or stage migration? Data from SWOG: S9346 and 8894

M Hussain;C Tangen;CS Higano;M Eisenberger;EJ Small;G Wilding;BJ Donnelly;D McLeod;ED Crawford;IM Thompson Proceedings of the American Society of Clinical Oncology 2010 Genitourinary Cancers Symposium, abst. 30; poster

2009

Cooperative group trials - Southwest Oncology Group (SWOG) innovations in advanced prostate cancer [PMID21085622; PMC2981166]

TB Dorff;C Tangen;ED Crawford;DP Petrylak;CS Higano;D Raghavan;DI Quinn;NJ Vogelzang;IM Thompson;MHA Hussain Therapeutic Advances in Medical Oncology 1(2):69-77;

2008

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

2007

Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916 [PMID17868721]

RB Montgomery;B Goldman;CM Tangen;M Hussain;DP Petrylak;S Page;EA Klein;ED Crawford Journal of Urology 178(5):1946-1951

2006

Prognostic value of hemoglobin change after initiation of androgen deprivations therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of SWOG 8894

TM Beer;BH Goldman;CM Tangen;LB Bland;M Hussain;TG DeLoughery;ED Crawford Proc of the AUA, Journal of Urology 175(4) Suppl:385-386, (#1197)

The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group study 8894

TM Beer;CM Tangen;L Bland;M Hussain;BH Goldman;TG DeLoughery;ED Crawford Cancer 107(3):489-496

2004

Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group study 8894

TM Beer;CM Tangen;LB Bland;IM Thompson;ED Crawford Journal of Urology 171(6, part 1 of 2):2213-2217

Prognostic value of anemia in untreated metastatic prostate cancer: a multivariate analysis of SWOG 8894

LB Bland;CM Tangen;IM Thompson;ED Crawford;TM Beer Proc of the American Society of Clinical Oncology 23:399 (#4574)

2003

Ten-year survival in patients with metastatic prostate cancer

CM Tangen;J Faulkner;ED Crawford;IM Thompson;D Hirano;M Eisenberger;M Hussain Clinical Prostate Cancer 2(1):41-45

Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning

TR Glass;CM Tangen;ED Crawford;I Thompson Journal of Urology 169:164-169

2002

Ten-year survival in patients with metastatic (M+) prostate cancer (CAP): analysis of Southwest Oncology Group (SWOG) 8894.

ED Crawford;J Faulkner;IM Thompson;M Eisenberger;C Tangen;M Hussain Journal of Urology 167(4)Suppl:304(#1202)

Impact of previous local treatment for prostate cancer on subsequent metastatic disease

IM Thompson;C Tangen;J Basler;ED Crawford Journal of Urology 168:1008-1012

Ten-year survival in patients wtih metastatic (M+) prostate cancer (CaP) analysis of Southwest Oncology Group (SWOG) 8894.

C Tangen;ED Crawford;J Faulkner;I Thompson;M Eisenberger;M Hussain Proc of the American Society of Clinical Oncology 21:188a(#749)

The relationship of gleason sum and survival in patients with metastatic (M+) prostate cancer (CaP): analysis of SWOG 8894.

ED Crawford;G Miller;J Faulkner;C Tangen;IM Thompson;M Eisenberger;M Hussain South Central Section of the AUA, 81st Annual Meetings :170(#31)

2001

Association of African American ethnic background with survival in men with metastatic prostate cancer.

IM Thompson;CM Tangen;A Tolcher;ED Crawford;M Eisenberger;CM Moinpour Journal of the National Cancer Institute 93(3):219-225

Does a prior radical prostatectomy (RP) alter outcome of hormonal therapy for metastatic (M+) prostate cancer (CAP)

IM Thompson;J Basler;C Tangen;ED Crawford Journal of Urology 165(5)Suppl:168(#689)

Response to letter to the editor: RE: association of African-American ethnic background with survival in men with metastatic prostate cancer.

A Tolcher;ED Crawford;M Eisenberger;CM Moinpour Journal of the National Cancer Institute 93(15):1175

2000

African American ethnic background is an independent and negative predictor of survival in metastatic prostate cancer

I Thompson;A Tolcher;ED Crawford;M Eisenberger;C Tangen;E Fisher Journal of Urology 163(4):56Suppl(#242)

Prognostic value of serum PSA in patients with newly diagnosed metastatic prostate cancer

D Crawford;I Thompson;A Tolcher Journal of Urology 163(4)Suppl:259(#1149)

1998

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

MA Eisenberger;BA Blumenstein;ED Crawford;G Miller;DG McLeod;PJ Loehrer;G Wilding;K Sears;DJ Culkin;IM Thompson Jr;AJ Bueschen;BA Lowe New England Journal of Medicine 339:1036-1042

1997

Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients (pts) with stage D2 adenocarcinoma of the prostate (CaP): Results of NCI Intergroup study 0105 (SWOG and ECOG).

ED Crawford;MA Eisenberger;DG McLeod;G Wilding;BA Blumenstein Journal of Urology 157(4):336(#1311)

A comparison of bilateral orchiectomy (orch) with or without flutamide in stage D2 prostate cancer (PC) (NCI INT-0105 SWOG/ECOG).

M Eisenberger;ED Crawford;D McLeod;P Loehrer;G Wilding;B Blumenstein Proc of the American Society of Clinical Oncology 16:2a(#3)

Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate: Results of the NCI intergroup study 0105 (SWOG and ECOG).

ED Crawford;M Eisenberger;DG McLeod;G Wilding;BA Blumenstein British Journal of Urology 80(Suppl.2):278(#1092)

1995

The prognostic significance of prostate specific antigen (PSA) in stage D2 prostate cancer (PC) interim evaluation of Intergroup study 0105

M Eisenberger;ED Crawford;D McLeod;M Hussain;P Loehrer;B Blumentstein ASCO 14:235(#613)

Overview analysis issues using combined androgen deprivation overview analysis as an example.

BA Blumenstein Urologic Oncology 1:95-100

1994

Treatment of histologically confirmed D2 prostate cancer - a comparison of bilateral orchiectomy with or without flutamide (intergroup study 0105)

ED Crawford;MA Eisenberger;B Blumenstein;DG McLeod;DJ Culkin;AJ Bueschen;IM Thompson;BA Lowe Urology 151(5):238A(#44)

1993

Some statistical considerations for the interpretation of trials of combined androgen therapy.

BA Blumenstein Cancer Supplement 72(12):3834-3840

Other Clinical Trials

SWOG Clinical Trial Number
SWOG-7303
SWOG Clinical Trial Number
SWOG-8221 (INT-0007)

Treatment of Advanced Bladder Cancer with Preoperative Irradiation and Radical Cystectomy versus Radical Cystectomy Alone

Research Committee(s)
Genitourinary Cancer
Activated
10/29/1982
Closed
11/15/1989
Accrual
81%
Closed
Published
SWOG Clinical Trial Number
SWOG-8216/38

Comparison of BCG Immunotherapy and Adriamycin for Superficial Bladder Cancer

Research Committee(s)
Genitourinary Cancer
Activated
12/01/1982
Closed
01/15/1987
Closed
Phase
III
Published